Hepatocellular carcinoma from the view of a transplant surgeon
Authors:
MUDr. Kočík Matěj 1; MUDr. Taimr Pavel 2; doc. MUDr. Froněk Jiří, Ph.D. 1
Authors place of work:
Klinika transplantační chirurgie, IKEM, Praha
1; Klinika hepatogastroenterologie, IKEM, Praha
2
Published in the journal:
Klin Onkol 2020; 33(Supplementum 3): 13-19
Category:
Review
doi:
https://doi.org/10.14735/amko20203S13
Summary
Curative treatments for hepatocellular carcinoma (HCC) traditionally include liver transplantation, liver resection, and in some very early HCCs, local ablation. Of these methods, transplantation brings the best long-term prognosis. Therefore, it should be considered by all multidisciplinary teams. Transplant treatment of HCC has developed significantly in recent years as does the concept of transplant oncology and in some centers HCC has already been the most common indication for liver transplantation. The aim of this work is to review the role of liver transplantation in the treatment of patients with HCC, its indications, results and the current situation in IKEM, the biggest transplantation center in the Czech Republic.
Keywords:
hepatocellular carcinoma – liver transplantation – transplant oncology
Zdroje
1. Adam R, Karam V, Cailliez V et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int 2018; 31 (12): 1293–1317. doi: 10.1111/tri.13358.
2. Eguchi S, Kanematsu T, Arii S et al. Recurrence – free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98 (4): 552–557. doi: 10.1002/bjs.7393.
3. Giuliante F, Ardito F, Pinna AD et al. Liver resection for hepatocellular carcinoma ≤ 3cm: results of an Italian multicenter study on 588 patients. J Am Coll Surg 2012; 215 (2): 244–254. doi: 10.1016/j.jamcollsurg.2012.04.013.
4. Pinna AD, Yang T, Mazzaferro V et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg 2018; 268 (5): 868–875. doi: 10.1097/SLA.0000000000002889.
5. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11): 693–699. doi: 10.1056/NEJM199603143341104.
6. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (6): 1394–1403. doi: 10.1053/jhep.2001.24563.
7. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (1): 35–43. doi: 10.1016/S1470-2045 (08) 70284-5.
8. Fan J, Yang GS, Fu ZR et al. Liver transplantation outcomes in 1078 hepatocellular carcinoma patients: a multi-center experience in Shanghai. J Cancer Res Clin Oncol 2009; 135 (10): 1403–1412. doi: 10.1007/s00432-009-0584-6.
9. Lee SG, Hwang S, Moon DB et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008; 14 (7): 935–945. doi: 10.1002/lt.21445.
10. Toso C, Meeberg G, Hernandez-Alejandro R et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 2015; 62 (1): 158–165. doi: 10.1002/hep.27787.
11. Duvoux C, Roudot-Thoraval F, Decaens T et al. Liver transplantation for hepatocellular carcinoma: a model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143 (4): 986–994. doi: 10.1053/j.gastro.2012.05.052.
12. Zheng SS, Xu X, Wu J et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85 (12): 1726–1732. doi: 10.1097/TP. 0b013e31816b67e4.
13. Kaido T, Ogawa K, Mori A et al. Usefulness of Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery 2013; 154 (5): 1053–1060. doi: 10.1016/j.surg.2013.04.056.
14. Sapisochin G, Goldaracena N, Laurence JM et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016; 64 (6): 2077–2088. doi: 10.1002/hep.28643.
15. Citores M, Lucena J, Fuente S et al. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019; 11 (1): 50–64. doi: 10.4254/wjh.v11.i1.50.
16. Abreu P, Gorgen A, Oldani G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Reports 2019; 1 (5): 377–391. doi: 10.1016/j.jhepr.2019.07.004.
17. Decaens T, Roudot-Thoraval F, Badran H et al. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liver Int 2011; 31 (6): 792–801. doi: 10.1111/j.1478-3231.2010.02425.x.
18. Cillo U, Vitale A, Bassanello M et al. Liver transplantation for the treatment of moderately or well differentiated hepatocellular carcinoma. Ann Surg 2004; 239 (2): 150–159. doi: 10.1097/01.sla.0000109146.72827.76.
19. Ravaioli M, Grazi GL, Piscaglia F et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8 (12): 254–757. doi: 10.1111/j.1600-6143.2008.02409.x.
20. Yao FY, Kerlan Jr RK, Hirose R et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48 (3): 819–827. doi: 10.1002/hep.22412.
21. Vibert E, Schwartz M, Olthoff K. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol 2020; 72 (2): 262–276. doi: 10.1016/j.jhep.2019.11.017.
22. Lee SM, Kim HS, Lee S. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25 (11): 1289–1306. doi: 10.3748/wjg.v25.i11.1289.
23. http: //www.hcc-olt-metroticket.org
24. Halazun KJ, Najjar M, Abdelmessih RM et al. Recurrence after liver transplantation for hepatocellular carcinoma. Ann Surg 2017; 265 (3): 557–564. doi: 10.1097/SLA.0000000000001966.
25. Mehta N, Heimbach J, Harnois D et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. AMA Oncol 2017; 3 (4): 493–500. doi: 10.1001/jamaoncol.2016.5116.
26. Firl D, Sasaki K, Agopian V et al. Charting the path forward for risk prediction in liver transplant for hepatocellular carcinoma: International validation of HALTHCC among 4,089 Patients. Hepatology 2020; 71 (2): 569–582. doi: 10.1002/hep.30838.
27. Muaddi H, Al-Adra D, Beecroft R et al. Liver transplantation is equally effective as a salvage therapy for patients with hepatocellular carcinoma recurrence following radiofrequency ablation or liver resection with curative intent. Ann Surg Oncol 2018; 25 (4): 991–999. doi: 10.1245/s10434-017-6329-x.
28. Cherqui D, Laurent A, Mocellin N et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250 (5): 738–746. doi: 10.1097/SLA.0b 013e3181bd582b.
29. Wang HL, Mo DC, Zhong J-H et al. Systematic review of treatment strategy for recurrent hepatocellular carcinoma: Salvage liver transplantation or curative locoregional therapy. Medicine 2019; 98 (8): e14498. doi: 10.1097/MD.0000000000014498.
30. Mazzaferro V, Citterio D, Bhoor S et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020; 21 (7): 947–956. doi: 10.1016/S1470-2045 (20) 30224-2.
31. Mehta N, Bhangui P, Yao F et al. Liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104 (6): 1136–1142. doi: 10.1097/TP.0000000000003174.
32. Eilard M, Andersson M, Naredi P et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer 2019; 19 (1): 568. doi: 10.1186/s12885-019-5760-8.
33. Kardashian A, Agopian V. Reply to: Role of sorafenib in liver transplantation outcomes of patients with hepatocellular carcinoma presenting beyond Milan criteria? Hepatology 2020; [in press]. doi: 10.1002/hep.31283.
34. Schwacha-Eipper B, Minciuna I, Banz V et al. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology 2020; [in press]. doi: 10.1002/hep.31234.
35. Lee D, Sapisochin G, Mehta N et al. Surveillance for HCC after Liver Transplantation: Increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation 2020; 104 (10): 2105–2112. doi: 10.1097/TP.0000000000003117.
36. Sapisochin G. et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol 2015; 22 (7): 2286–2294. doi: 10.1245/s10434-014-4273-6.
37. Ekpanyapong S, Philips N, Loza B et al. Predictors, presentation, and treatment outcomes of recurrent hepatocellular carcinoma after liver transplantation: A large single center experience. J Clin Exp Hepatol 2020; 10 (4): 304–315. doi: 10.1016/j.jceh.2019.11.003.
38. Yang Z, Wang S, Tian XY et al. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: preliminary experience. Hepatobiliary Pancreat Dis Int; 19 (4): 365–370. doi: 10.1016/ j.hbpd.2020.06.002.
39. Invenizzi F, Iavarone M, Donato MF et al. Pulmonary resection for metastasis of hepatocellular carcinoma recurring after liver transplant: An Italian multicenter experience. Front Oncol 2020; 10: 38. doi: 10.3389/fonc.2020.00381.
40. de’Angelis N, Landi F, Carra MC et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol 2015; 21 (39): 11185–11198. doi: 10.3748/wjg.v21.i39.11185.
41. Hu B, Yang XB, Sang XT. Liver graft rejection following immune checkpoint inhibitors treatment: a review. Medical Oncology 2019; 36 (11): 94. doi: 10.1007/s12032-019-1316-7.
42. Berenguer M, Burra P, Ghobrial M et al. Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104 (6): 1143–1149. doi: 10.1097/TP.0000000000003196.
43. Mergental H, Adam R, Ericzon BG et al. Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol 2012; 57 (2): 297–305. doi: 10.1016/j.jhep.2012.03.022.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2020 Číslo Supplementum 3
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Hepatocellular carcinoma future treatment options
- Current treatment options for hepatocellular carcinoma
- Hepatocellular carcinoma from the view of gastroenterologist/hepatologist
- Hepatocellular carcinoma – imaging methods and imaging guided therapy